Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. increased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 2.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,228,394 shares of the company's stock after acquiring an additional 80,639 shares during the quarter. Vanguard Group Inc. owned about 5.60% of Protagonist Therapeutics worth $53,850,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. State Street Corp lifted its position in Protagonist Therapeutics by 108.1% during the second quarter. State Street Corp now owns 6,776,269 shares of the company's stock valued at $53,600,000 after purchasing an additional 3,519,461 shares during the last quarter. BlackRock Inc. lifted its position in Protagonist Therapeutics by 13.8% during the second quarter. BlackRock Inc. now owns 5,009,273 shares of the company's stock valued at $138,356,000 after purchasing an additional 607,056 shares during the last quarter. Morgan Stanley lifted its position in Protagonist Therapeutics by 9.5% during the fourth quarter. Morgan Stanley now owns 2,438,517 shares of the company's stock valued at $26,604,000 after purchasing an additional 210,942 shares during the last quarter. Kynam Capital Management LP lifted its position in Protagonist Therapeutics by 86.5% during the third quarter. Kynam Capital Management LP now owns 1,818,657 shares of the company's stock valued at $30,335,000 after purchasing an additional 843,359 shares during the last quarter. Finally, Perceptive Advisors LLC lifted its position in Protagonist Therapeutics by 52.3% during the second quarter. Perceptive Advisors LLC now owns 1,469,761 shares of the company's stock valued at $40,595,000 after purchasing an additional 504,609 shares during the last quarter. Institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Stock Up 3.7 %

PTGX stock traded up $1.04 during trading on Tuesday, hitting $29.13. The company had a trading volume of 885,934 shares, compared to its average volume of 732,349. The firm has a market capitalization of $1.70 billion, a P/E ratio of -18.85 and a beta of 2.02. Protagonist Therapeutics, Inc. has a 52-week low of $13.72 and a 52-week high of $33.34. The company has a 50 day simple moving average of $28.42 and a 200-day simple moving average of $22.38.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.05 by $0.39. The company had revenue of $60.00 million during the quarter, compared to analysts' expectations of $60.00 million. Sell-side analysts forecast that Protagonist Therapeutics, Inc. will post 1.18 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of Protagonist Therapeutics from $34.00 to $37.00 and gave the company an "overweight" rating in a research note on Wednesday, February 28th. HC Wainwright reissued a "buy" rating and issued a $38.00 target price on shares of Protagonist Therapeutics in a research note on Wednesday, February 28th. Finally, StockNews.com raised shares of Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $36.00.

Insider Buying and Selling

In related news, CEO Dinesh V. Ph D. Patel sold 25,000 shares of the firm's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $28.31, for a total value of $707,750.00. Following the transaction, the chief executive officer now owns 549,590 shares of the company's stock, valued at approximately $15,558,892.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Protagonist Therapeutics news, Director William D. Waddill sold 12,975 shares of the firm's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $31.34, for a total transaction of $406,636.50. Following the transaction, the director now owns 12,000 shares of the company's stock, valued at approximately $376,080. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 25,000 shares of the firm's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $28.31, for a total transaction of $707,750.00. Following the transaction, the chief executive officer now directly owns 549,590 shares in the company, valued at approximately $15,558,892.90. The disclosure for this sale can be found here. Insiders have sold 82,223 shares of company stock valued at $2,522,342 in the last 90 days. Company insiders own 5.00% of the company's stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.